22:52:36 EST Tue 25 Feb 2020
Enter Symbol
or Name

Login ID:
Trillium Therapeutics Inc (2)
Symbol TRIL
Shares Issued 28,038,831
Close 2020-01-22 C$ 4.28
Recent Sedar Documents

Trillium arranges public offering of shares, preferreds

2020-01-22 16:18 ET - News Release

Mr. James Parsons reports


Trillium Therapeutics Inc. has commenced a public offering of common shares of the company and Series 2 non-voting convertible first preferred shares of the company. In addition, Trillium intends to grant the underwriters a 30-day option to purchase up to an additional amount of common shares equal to 15 per cent of the common shares and Series 2 first preferred shares offered in the offering.

The Series 2 first preferred shares are being offered to investors whose purchase of common shares in the offering may result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99 per cent of the company's outstanding common shares following the consummation of the offering.

The company intends to use the net proceeds of the offering for: (i) the clinical development of its CD47 programs; and (ii) working capital and general corporate purposes.

Cowen is acting as the sole bookrunning manager for the offering.

No common shares or Series 2 first preferred shares will be offered or sold in Canada as part of this offering. The offering is subject to market conditions, as well as a number of closing conditions, including Nasdaq Capital Market and Toronto Stock Exchange approvals, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. For the purposes of TSX approval, the company intends to rely on the exemption set forth in Section 602.1 of the TSX company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

The offering is being made to purchasers outside of Canada pursuant to a U.S. registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commission on Jan. 8, 2018, and the company's existing Canadian short-form base-shelf prospectus dated Jan. 5, 2018. A preliminary prospectus supplement dated Jan. 22, 2020, has been filed relating to the offering, and a final prospectus supplement relating to the offering will be filed with the securities commissions in the provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia in Canada, and with the SEC in the United States.

The offering documents will contain important detailed information about the securities being offered. Before you invest, you should read the offering documents and the other documents the company has filed for more complete information about the company and the offering. Copies of the offering documents will be available at no charge by visiting the company's profile on the SEDAR website maintained by the Canadian Securities Administrators or the SEC's website, as applicable. Alternatively, copies of the prospectus supplement will be available upon request by contacting Cowen and Company LLC care of Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, N.Y., 11717, attention: prospectus department, by e-mail at PostSaleManualRequests@broadridge.com or by telephone at 833-297-2926.

About Trillium Therapeutics Inc.

Trillium is an immuno-oncology company, developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a do-not-eat signal that cancer cells frequently use to evade the immune system.

The company's pipeline also includes a preclinical Sting (stimulator of interferon genes) agonist program. As previously announced, the program is earmarked for outlicensing.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.